Top in endocrinology: Time-restricted eating; tirzepatide fast track designation
Click Here to Manage Email Alerts
Combining time-restricted eating with high-intensity interval training led to greater reductions in visceral fat among women compared with either intervention alone, according to a recent study.
The combination of interventions also led to decreased body weight and fat mass, as well as improvements in peak oxygen uptake. It was the top story in endocrinology last week.
Another top story was about the FDA’s fast track designation for tirzepatide (Mounjaro, Eli Lilly) to treat adults with obesity or overweight with weight-related comorbidities. The drug was previously approved by the FDA in May for the treatment of adults with type 2 diabetes.
Read these and more top stories in endocrinology below:
Time-restricted eating plus high-intensity exercise lower visceral fat for women Women who combine time-restricted eating with high-intensity interval training have greater reductions in visceral fat area than those who perform only one of the interventions, according to a study published in Cell Metabolism. Read more.
FDA grants fast track designation to tirzepatide to treat obesity, overweight
Today, Eli Lilly and Company received FDA fast track designation for tirzepatide to treat adults with obesity or overweight with weight-related comorbidities. Read more.
Type 2 diabetes remission likely for adults with ‘healthy’ BMI and 10% weight loss
Adults with type 2 diabetes and a BMI of 21 kg/m2 to 27 kg/m2 have high likelihood of diabetes remission if they lose 10% of their starting weight, researchers reported. Read more.
GRADE: Insulin glargine, liraglutide better maintain glycemic control than other agents
Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to data from the GRADE trial. Read more.
HbA1c less than 7% recommended in type 1 diabetes to avoid retinopathy, nephropathy
Study results published in Diabetes Care highlight the importance of maintaining HbA1c lower than 7% to avoid proliferative diabetic retinopathy and macroalbuminuria for people with type 1 diabetes. Read more.